LENZ Therapeutics

Historical price data

LENZ Therapeutics is focused on developing and commercializing innovative ophthalmic therapies, with its lead program targeting the vast, underserved market of presbyopia. The company's key achievement is the FDA approval of VIZZ™, a proprietary aceclidine-based eye drop designed to restore near vision by creating a 'pinhole camera' effect through pupil constriction. Its strategy involves a direct U.S. commercial launch while pursuing international licensing partnerships to maximize global reach. LENZ aims to establish VIZZ™ as the standard of care in pharmaceutical presbyopia treatment.

Proprietary formulation platform optimizing known miotic agents, primarily aceclidine, to modulate pupil size and increase depth of focus for the treatment of presbyopia via a once-daily eye drop.